- Home
- VRPX vs TCBP Comparison
VRPX vs TCBP Comparison
Compare VRPX & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRPX
- TCBP
- Stock Information
- Founded
- VRPX 2016
- TCBP 2013
- Country
- VRPX United States
- TCBP United Kingdom
- Employees
- VRPX N/A
- TCBP N/A
- Industry
- VRPX Medicinal Chemicals and Botanical Products
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRPX Health Care
- TCBP Health Care
- Exchange
- VRPX Nasdaq
- TCBP Nasdaq
- Market Cap
- VRPX 3.3M
- TCBP 3.0M
- IPO Year
- VRPX 2021
- TCBP 2022
- Fundamental
- Price
- VRPX $0.64
- TCBP $7.59
- Analyst Decision
- VRPX Strong Buy
- TCBP
- Analyst Count
- VRPX 1
- TCBP 0
- Target Price
- VRPX $3.00
- TCBP N/A
- AVG Volume (30 Days)
- VRPX 52.5K
- TCBP 198.5K
- Earning Date
- VRPX 11-13-2024
- TCBP 11-09-2024
- Dividend Yield
- VRPX N/A
- TCBP N/A
- EPS Growth
- VRPX N/A
- TCBP N/A
- EPS
- VRPX N/A
- TCBP N/A
- Revenue
- VRPX N/A
- TCBP N/A
- Revenue This Year
- VRPX N/A
- TCBP N/A
- Revenue Next Year
- VRPX N/A
- TCBP N/A
- P/E Ratio
- VRPX N/A
- TCBP N/A
- Revenue Growth
- VRPX N/A
- TCBP N/A
- 52 Week Low
- VRPX $0.46
- TCBP $2.11
- 52 Week High
- VRPX $9.00
- TCBP $1,140.00
- Technical
- Relative Strength Index (RSI)
- VRPX 34.79
- TCBP 62.72
- Support Level
- VRPX $0.63
- TCBP $6.01
- Resistance Level
- VRPX $0.70
- TCBP $6.71
- Average True Range (ATR)
- VRPX 0.05
- TCBP 0.75
- MACD
- VRPX 0.00
- TCBP 0.07
- Stochastic Oscillator
- VRPX 6.21
- TCBP 92.83
About VRPX Virpax Pharmaceuticals Inc.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.